The MarketWatch News Department was not involved in the creation of this content.
Sep 13, 2020 (AmericaNewsHour) —
Europe Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases.Europe is a market with stable growth for conjugate vaccines. The conjugate vaccine market in Europe is expected to expand at a CAGR of 3.6% leading to a revenue of USD 8.94 Bn by 2023. By volume, it is anticipated to reach 504.46 Million units by 2023, expanding at a CAGR of 3.7%. The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained.
Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10009588
- Based on disease indication, the market